

20 April 2026

ASX Market Announcements Office

Dear Sir or Madam

Appendix 3Y Clarification

The Company advises that in previously lodged Appendix 3Y's for the Executive Chair and CEO, Chiat Thian Chew, the notices did not include disclosure of certain interests held by Mr Honsue Cho and his associates, on the basis that such disclosure was not strictly required to comply with the ASX Listing Rules. The Invion board has determined however that for good corporate governance a revised Appendix 3Y should be lodged for Mr Chew to align with disclosures in the recent substantial holder notice for Mr Honsue Cho and associates lodged with ASX on 8 April 2026.

An updated Appendix 3Y has been lodged with the ASX today.

The Company confirms that it remains in compliance with ASX Listing Rules 3.19A and 3.19B, which require timely and accurate disclosure of directors' relevant interests and the implementation of appropriate arrangements to ensure such compliance.

- ENDS -

Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions: <https://investors.inviongroup.com/>

Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

ASX ANNOUNCEMENT

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".